NORE1 (RASSF5) (NM_182665) Human Tagged ORF Clone Lentiviral Particle

SKU RC203854L2V

Lenti ORF particles, RASSF5 (mGFP-tagged) - Human Ras association (RalGDS/AF-6) domain family member 5 (RASSF5), transcript variant 3, 200ul, >10^7 TU/mL

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: mGFP
• Target Symbol: NORE1
• Synonyms: Maxp1; NORE1; NORE1A; NORE1B; RAPL; RASSF3
• Vector: pLenti-C-mGFP
• Mammalian Cell Selection: None
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC203854).
• ACCN: NM_182665
• ORF Size: 795 bp
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
• Shipping: Dry Ice

Reference Data

• RefSeq: NM_182665.2
• RefSeq Size: 3531 bp
• RefSeq ORF: 798 bp
• Locus ID: 83593
• UniProt ID: Q8WWW0
• Cytogenetics: 1q32.1
• Protein Families: Druggable Genome
• Protein Pathways: Leukocyte transendothelial migration, Non-small cell lung cancer, Pathways in cancer
• MW: 30.4 kDa
• Summary: This gene is a member of the Ras association domain family. It functions as a tumor suppressor, and is inactivated in a variety of cancers. The encoded protein localizes to centrosomes and microtubules, and associates with the GTP-activated forms of Ras, Rap1, and several other Ras-like small GTPases. The protein regulates lymphocyte adhesion and suppresses cell growth in response to activated Rap1 or Ras. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]